Pancreatic Cancer Therapeutics and Diagnostic Market, By Type (Treatment (Targeted Therapies, Chemotherapy, Surgery, and Other Treatments) and Diagnostics (Imaging, Biopsy, Endoscopic Ultrasound, and Other Diagnostics), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
Pancreatic cancer is cancer that forms in the cells of the pancreas. Pancreatic cancer occurs when changes (mutations) in the pancreas cells lead them to multiply out of control. The cancer can be diagnosed with the help of ultrasound, computerized tomography (CT) scans, magnetic resonance imaging (MRI) and positron emission tomography (PET) scans. Treatment may include surgery, radiation, chemotherapy, or a combination of these.
Market Dynamics:
Rise in incidence and prevalence of pancreatic cancer, rise in development of novel therapeutics, growing geriatric population, increase in demand for safe and effective therapeutics, and increase in awareness among people are major factors expected to augment growth of the global pancreatic cancer therapeutics and diagnostic market.
For instance, in January 2021, Myriad Genetics Inc. and Illumina Inc. collaborated to develop a kit-based version of the myChoice companion diagnostic test for international markets, which can be used to detect pancreatic cancer.
Moreover, in September 2020, the Indian Council of Medical Research (ICMR)-National Institute of Cancer Prevention and Research (NICPR) launched www.cancerindia.org with the theme ‘India against Cancer, a portal that provides information on the leading cancers in India with the major focus on awareness, prevention, and treatment of cancers, including pancreatic cancer.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook